Dr. Elli Papaemmanuil‘s paper led by Bolton, et al. followed a large cohort (25K) of solid tumor patients retrospective including longitudinal samples from 525 individuals. They show how different oncologic therapies and other environmental stressors promotes the expansion of hematopoietic stem/progenitor cells bearing specific mutations. The group then went on to show what mutational features of clonal hematopoiesis put solid tumor patients at the highest risk for the development of therapy-related myeloid disease and how this might be clinically meaningful.
Dr. Kelly Bolton explains further in her multi-part Twitter commentary linked below:
Learn more in Dr. Bolton’s blog post, or read the related paper in Nature Genetics here.